Browse > Article

Four-Week Repeated Dose Toxicity Study of a Novel HepatitisB Virus-Immunotherapeutic Agent, MBRI-98304,in Rats and Beagle Dogs  

Hwang, Jae-Sik (충북대학교)
Jang, Ho-Song (충북대학교)
Sin, Ji-Sun (충북대학교)
Jeong, Eun-Yong (충북대학교)
Gang, Min-Jeong (충북대학교)
Gwon, Yeong-Bang (충북대학교)
Kim, Yun-Bae (충북대학교)
Gang, Jong-Gu (충북대학교)
Publication Information
Laboraroty Animal Research / v.18, no.1, 2002 , pp. 37-48 More about this Journal
Abstract
To investigate the repeated toxicity of MBRI·98304, a novel immunotherapeutic agent against hepatitis B virus (HBV), we performed 4-week repeated dose toxicity tests in Sprague-Dawley (SD) rats and Beagle dogs. MBRI-98304 was injected subcutaneously in rats and intramuscularly in dogs everyday for 28 days at doses of 5, 50, or 500 $\mu$g/kg, respectively. No clinical signs or mortality were observed in animals treated with MBRI·98304 throughout the experimental period. Also, there were no significant changes in body weights, feed intake, water consumption, and any gross or histopathological lesions. Although, there were statistically-significant differences between the control and treated groups in urinalysis, relative and absolute organ weights, and hematological and biochemical analyses, the data were in biologically normal ranges and did not show a dose-dependent manner. Taken together, it is proposed that toxic dose levels of MBRI·98304 in both rats and dogs may be over 500 $\mu$g/kg
Keywords
HepatitisB virus (HBV), MBRI-98304, immunotherapeutic agent, repeated toxicity, rats, beagle dogs
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hsu HM, Lu CF, Lee SC, Lin SR & Chen DS (1999): Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J. Infect. Dis. 179: 360-367   DOI   ScienceOn
2 Chang JS, Choi MJ, Cheong HS & Kim K (2001): Development of Thl-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine. 19(27): 3608-3614   DOI   ScienceOn
3 Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, Lafond R, Yuan L, Chisari FV, Furze J & Bartholomeuz R (1995): Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95(1): 341-349   DOI   ScienceOn
4 Yale CE & Balish E (1976): Blood and serum chemistry values of gnotobiotic Beagles. Lab. Anim. Sci. 26: 633-639
5 內山智晴, 常井和男, 出來俊昭 (1985): 實驗用ビ-グル犬の成長に伴 う血液學的ならぴ血淸生化學的性狀の變化. 實驗動物. 34: 367-377
6 Earl FL, Melveger BE & Wilson RL (1973): The hemogram & bone marrow profile of normal neonate & weanling dogs. Lab. Anim. Sci. 23: 690-695
7 Edmunds WJ, Medley GF, Nokes DJ, Hall AJ & Whittle HC (1993): The influence of age on the development of the hepatitis B carrier state. Proc. R Soc. Lond B Biol. Sci. 253: 197-201   DOI   ScienceOn
8 Marques AR & Straus SE (1998): Advances in the treatment of chronic hepatitis B virus infection. Rev. Med. Virol. 8: 223-234   DOI   ScienceOn
9 Wolford ST, Schroer RA, Gohs FX, Gallo PP, Brodeck M, Falk HB & Ruhren R (1986): Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environm. Health. 18: 161-168   DOI   ScienceOn
10 Byars NE, Nakano G, Welch M, Lehman D & Allison AC (1991): Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine. 9(5): 309-318   DOI   ScienceOn
11 Hercas-Stubbs S, Berasain C, Golvano JJ, Lasarte JJ, Prieto I, Sarobe P, Prieto J & Borras-Cuesta F (1994): Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine 12(10): 867-871   DOI   ScienceOn